KLRS — Kalaris Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
$3.97
+$0.05 (+1.28%)
Kalaris Therapeutics, Inc. (KLRS) is a biotechnology company listed on NASDAQ. It is led by Andrew Oxtoby, based in 628 Middlefield Road, Palo Alto, CA, United States, 94301, with about 14 employees. Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California.
Net income was -$33.4M.
Use this KLRS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the KLRS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the KLRS SEC filings page. Lician reads the product cache first so this HTML stays unique to Kalaris Therapeutics, Inc. even when a live quote feed is slow.
About Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California.
KLRS Key Statistics
Market Cap
$0.00M
Volume
26,257
Previous Close
$4.10
Day Range
$4.04 – $4.25
EPS
-$11.73
Revenue
$0.00
Net Income
-$58.77M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
14
KLRS Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$58.77M | -$190.42M | -$168.71M | -$171.96M |
| EPS (Diluted) | -$11.73 | -$42.09 | -$2.20 | -$2.74 |
Total Assets
$118.55M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$118.29M
Operating Cash Flow
-$67.70M
Free Cash Flow
$0.00
Kalaris Therapeutics, Inc. Company Information
- President, CEO & Director
- Andrew Oxtoby
- Headquarters
- 628 Middlefield Road, Palo Alto, CA, United States, 94301
- Website
- kalaristx.com
- IPO / Founded
- 2020-07-30
- Sector
- Healthcare
- Industry
- Biotechnology